• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

黑尿症患者骨质疏松症诊断与管理中的困境：特立帕肽治疗成功案例

Dilemmas in the diagnosis and management of osteoporosis in a patient with alkaptonuria: Successful treatment with teriparatide.

作者信息

Ebrahim Ismail C, Hoang Thanh D, Vietor Nicole O, Schacht John P, Shakir Mohamed K M

机构信息

Division of Endocrinology, Department of Medicine Walter Reed National Military Medical Center Bethesda Maryland USA.

Division of Endocrinology, Department of Medicine Uniformed Service University of the Health Sciences Bethesda Maryland USA.

出版信息

Clin Case Rep. 2022 Dec 27;10(12):e6729. doi: 10.1002/ccr3.6729. eCollection 2022 Dec.

DOI:10.1002/ccr3.6729
PMID:36583204
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9794677/
Abstract

Management of osteoporosis in patients with alkaptonuria can be challenging. This is the first case report confirming the effectiveness of teriparatide following zoledronic acid therapy in treating osteoporosis and preventing fragility fractures in a patient with alkaptonuria.

摘要

对于患有黑尿症的患者，骨质疏松症的管理可能具有挑战性。这是首例证实唑来膦酸治疗后使用特立帕肽治疗骨质疏松症并预防黑尿症患者脆性骨折有效性的病例报告。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/9794677/3d72df295ae9/CCR3-10-e6729-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/9794677/452e17518968/CCR3-10-e6729-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/9794677/7f5d37386994/CCR3-10-e6729-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/9794677/3d72df295ae9/CCR3-10-e6729-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/9794677/452e17518968/CCR3-10-e6729-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/9794677/7f5d37386994/CCR3-10-e6729-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/9794677/3d72df295ae9/CCR3-10-e6729-g001.jpg

相似文献

1
Dilemmas in the diagnosis and management of osteoporosis in a patient with alkaptonuria: Successful treatment with teriparatide.黑尿症患者骨质疏松症诊断与管理中的困境：特立帕肽治疗成功案例
Clin Case Rep. 2022 Dec 27;10(12):e6729. doi: 10.1002/ccr3.6729. eCollection 2022 Dec.
2
Treatment of osteoporotic fractures in alkaptonuria by teriparatide stimulates bone formation and decreases fracture rate - A report of two cases.特立帕肽治疗尿黑酸尿症骨质疏松性骨折可刺激骨形成并降低骨折率——两例报告
Bone Rep. 2021 Nov 28;15:101151. doi: 10.1016/j.bonr.2021.101151. eCollection 2021 Dec.
3
Frequency, diagnosis, pathogenesis and management of osteoporosis in alkaptonuria: data analysis from the UK National Alkaptonuria Centre.尿黑酸尿症中骨质疏松症的频率、诊断、发病机制和管理：来自英国国家尿黑酸尿症中心的数据分析。
Osteoporos Int. 2021 May;32(5):927-938. doi: 10.1007/s00198-020-05671-y. Epub 2020 Oct 29.
4
Effects of bone remodeling agents following teriparatide treatment.骨重建药物对特立帕肽治疗后的影响。
Osteoporos Int. 2018 Jun;29(6):1351-1357. doi: 10.1007/s00198-018-4434-8. Epub 2018 Mar 14.
5
Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.骨质疏松症中特立帕肽的治疗模式及后续骨折事件：一项美国索赔分析。
Osteoporos Int. 2015 Mar;26(3):1203-12. doi: 10.1007/s00198-014-2971-3. Epub 2015 Jan 8.
6
The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS).特立帕肽治疗对绝经后骨质疏松症女性脆性骨折风险的影响：亚洲和拉丁美洲骨折观察研究（ALAFOS）的结果。
Calcif Tissue Int. 2022 Jan;110(1):74-86. doi: 10.1007/s00223-021-00895-4. Epub 2021 Aug 20.
7
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.地舒单抗、雷洛昔芬、罗莫佐单抗和特立帕肽预防骨质疏松性脆性骨折：系统评价和经济评估。
Health Technol Assess. 2020 Jun;24(29):1-314. doi: 10.3310/hta24290.
8
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.唑来膦酸、特立帕肽、地舒单抗和伊班膦酸治疗绝经后骨质疏松症的疗效和安全性：一项随机对照试验的网络荟萃分析。
Eur Rev Med Pharmacol Sci. 2023 Sep;27(17):8253-8268. doi: 10.26355/eurrev_202309_33586.
9
Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.在老年严重骨质疏松症患者中，从特立帕肽转换为唑来膦酸或地舒单抗对骨密度和骨转换生化标志物的疗效：一项真实世界研究。
Endocrine. 2023 Oct;82(1):181-189. doi: 10.1007/s12020-023-03431-6. Epub 2023 Jul 4.
10
Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.地诺单抗、特立帕肽和唑来膦酸在体弱老年人中的比较疗效：一项回顾性队列研究。
Osteoporos Int. 2021 Mar;32(3):565-573. doi: 10.1007/s00198-020-05732-2. Epub 2021 Jan 7.

引用本文的文献

1
Alkaptonuria.黑尿症
Nat Rev Dis Primers. 2024 Mar 7;10(1):16. doi: 10.1038/s41572-024-00498-x.

本文引用的文献

1
Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.比较2毫克和10毫克尼替西农治疗尿黑酸尿症——一种使用统计建模的方法
JIMD Rep. 2021 Nov 11;63(1):80-92. doi: 10.1002/jmd2.12261. eCollection 2022 Jan.
2
Treatment of osteoporotic fractures in alkaptonuria by teriparatide stimulates bone formation and decreases fracture rate - A report of two cases.特立帕肽治疗尿黑酸尿症骨质疏松性骨折可刺激骨形成并降低骨折率——两例报告
Bone Rep. 2021 Nov 28;15:101151. doi: 10.1016/j.bonr.2021.101151. eCollection 2021 Dec.
3
Frequency, diagnosis, pathogenesis and management of osteoporosis in alkaptonuria: data analysis from the UK National Alkaptonuria Centre.
尿黑酸尿症中骨质疏松症的频率、诊断、发病机制和管理：来自英国国家尿黑酸尿症中心的数据分析。
Osteoporos Int. 2021 May;32(5):927-938. doi: 10.1007/s00198-020-05671-y. Epub 2020 Oct 29.
4
Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.尼替西农治疗后黑酸尿症中褐黄病色素沉着的逆转：来自英国国家黑酸尿症中心的数据分析
JIMD Rep. 2020 Jun 22;55(1):75-87. doi: 10.1002/jmd2.12137. eCollection 2020 Sep.
5
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.每日一次尼替西农治疗尿黑酸尿症患者的疗效和安全性（SONIA 2）：一项国际、多中心、开放标签、随机对照试验。
Lancet Diabetes Endocrinol. 2020 Sep;8(9):762-772. doi: 10.1016/S2213-8587(20)30228-X. Epub 2020 Aug 18.
6
Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype-phenotype correlations in the largest cohort of patients with AKU.高胱氨酸 1,2-双加氧酶（HGD）基因变异体及其在最大 AKU 患者队列中的分析和基因型-表型相关性。
Eur J Hum Genet. 2019 Jun;27(6):888-902. doi: 10.1038/s41431-019-0354-0. Epub 2019 Feb 8.
7
Musculoskeletal manifestations of alkaptonuria: A case report and literature review.黑尿症的肌肉骨骼表现：一例病例报告及文献综述
Eur J Rheumatol. 2018 Nov 16;6(2):98-101. doi: 10.5152/eurjrheum.2018.18116. Print 2019 Apr.
8
The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.尼替西农对尿黑酸和酪氨酸的影响：对利物浦国家黑尿症中心患者的两年调查
Ann Clin Biochem. 2017 May;54(3):323-330. doi: 10.1177/0004563217691065. Epub 2017 Mar 16.
9
Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing.黑尿病骨关节炎中的软骨生物标志物显示出低周转率和加速老化。
Rheumatology (Oxford). 2017 Jan;56(1):156-164. doi: 10.1093/rheumatology/kew355. Epub 2016 Oct 7.
10
Alkaptonuria: An example of a "fundamental disease"--A rare disease with important lessons for more common disorders.黑尿症：一种“基本疾病”的实例——一种罕见疾病，对更常见疾病有重要启示。
Semin Cell Dev Biol. 2016 Apr;52:53-7. doi: 10.1016/j.semcdb.2016.02.020. Epub 2016 Feb 16.